文献速递中枢神经肿瘤放疗姑息放疗与转移瘤

大体积脑转移瘤的局部治疗与软脑膜播散风险

Focal Management of Large Brain Metastases and Risk of Leptomeningeal Disease.
PubMed 文献 · Adv Radiat Oncol · 2019-08-05

该回顾性研究比较手术切除后立体定向放疗(S+SRS)与单纯分次立体定向放疗(FSRT)治疗直径≥3cm脑转移瘤的软脑膜播散(LMD)和局部控制(LC)。共125例患者,S+SRS组82例,FSRT组43例。结论提示S+SRS可能增加LMD风险,而FSRT可作为特定患者的替代选择。

要点

  • FSRT可作为特定大体积脑转移瘤患者替代S+SRS的选择。

核心结论

  • 手术切除后立体定向放疗(S+SRS)可能较单纯分次立体定向放疗(FSRT)增加软脑膜播散(LMD)风险,但局部控制相似。

研究设计与样本

  • 回顾性研究纳入2004至2017年接受S+SRS或FSRT(25或30 Gy分5次)治疗且直径≥3cm脑转移瘤并有随访影像的患者,共125例(S+SRS组82例,FSRT组43例)。

关键数值与推荐

  • LMD定义为距离原转移灶>5mm的局灶或弥漫性软脑膜强化。
  • FSRT剂量方案为25或30 Gy分5次。

临床怎么用

  • 对于特定大体积脑转移瘤患者,FSRT可作为S+SRS的可行替代方案,尤其需权衡LMD风险。
  • 手术仍适用于某些脑转移瘤,但S+SRS后应关注LMD风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Surgery is often used for large or symptomatic brain metastases but is associated with risk of developing leptomeningeal dissemination. Emerging data suggest that fractionated stereotactic radiation therapy (FSRT) is an effective management strategy in large brain metastases. We sought to retrospectively compare leptomeningeal disease (LMD) and local control (LC) rates for patients treated with surgical resection followed by radiosurgery (S + SRS) versus FSRT alone. METHODS AND MATERIALS: We identified all patients with a brain metastasis ≥3 cm in diameter treated from 2004 to 2017 with S + SRS or FSRT alone (25 or 30 Gy in 5 fractions) who had follow-up imaging. LMD was defined as focal or diffuse leptomeningeal enhancement that was >5 mm from the index metastasis. Categorical baseline characteristics were compared with the χ2 test. LMD and LC rates were evaluated by the Kaplan-Meier (KM) method, with the log-rank test used to compare subgroups. RESULTS: A total of 125 patients were identified, including 82 and 43 in the S + SRS and FSRT alone groups, respectively. Median pretreatment Graded Prognostic Assessment in the S + SRS and FSRT groups was 2.5 and 1.5, respectively (P < .001). Median follow-up was 7 months. The KM estimate of 12-month LMD rate in the S + SRS and FSRT groups was 45% and 19%, respectively (P = .048). The KM estimate of 12-month local control in the S + SRS and FSRT groups was 70% and 69%, respectively (P = .753). The 12-month KM estimate of grade ≥3 toxicity was 1.4% in S + SRS group versus 6.3% in the FSRT alone group (P = .248). After adjusting for graded prognostic assessment (GPA), no overall survival difference was observed between groups (P = .257). CONCLUSIONS: Surgery is appropriate for certain brain metastases, but S + SRS may increase LMD risk compared with FSRT alone. Because S + SRS and FSRT seem to have similar LC, FSRT may be a viable alternative to S + SRS in select patients with large brain metastases.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Marcrom SR, Foreman PM, Colvin TB, et al. Focal Management of Large Brain Metastases and Risk of Leptomeningeal Disease. Adv Radiat Oncol. 2019. PMID: 32051888. doi:10.1016/j.adro.2019.07.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。